The Gap Between Clinician-led Cell Therapy and Marketed Products: Pilot study of young ventures
Presented at 2019 American Society for Cell and Gene Therapy (ASGCT) in Washington, DC. Hemophilia is an important sector within biotech, and one of the largest rare disease markets. Design of clinical trials with consideration for the recent regulatory landscape is central for cell and gene therapy biotech firms in this space. This talk focused on:
https://biotechmentor.com/wp-content/uploads/2020/04/Cell-therapy-poster-2019-3.pdf
Attendees learned about:
- Gaining Insights into a Successful Hemophilia Gene Therapy Trial
- Overviewing standard outcomes measures and recent surrogate endpoints,
safety measures, and patient important outcomes (PIOs) and patient reported
outcomes (PROs) - Understanding logistical considerations for early trial clinical development and
scalable clinical product management - Examining patient selection and retention in hemophilia advanced therapy trials
Share the Knowledge.
Science and business are about sharing knowledge. I encourage you to use, modify, and adapt my materials for educational and non-commercial purposes. When you do, please remember to acknowledge me, the original author. Please contact me with any questions.
Preferred citation:
Johnson, A.N. [Workshop] Strategic Gene Therapy Product Platforms and Partnerships: From Codevelopment to Companion Products. Gene Therapy for Rare Blood Disorders March 3-5, 2020. Boston, MA USA. Accessed online at https://biotechmentor.com/portfolio/strategic-gene-therapy-platforms-partnerships-diagnostics-and-codevelopment/
You can download this poster here.
